Hepion Pharma CEO Kaouthar Lbiati resigns; Gary Stetz named interim CEO

Hepion Pharmaceuticals, Inc.

CEO Dr. Kaouthar Lbiati resigned effective March 16, 2026, for personal reasons.
Board appointed Gary Stetz as interim CEO and director; Vincent LoPriore as Executive Chairman.
Sireesh Appajosyula and Chase LoPriore also appointed to the board of directors.
No family relationships or arrangements between new appointees and other officers disclosed.

item 5.02

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.